DLA Piper has advised Medtronic Global Holdings S.C.A. ("Medtronic LuxCo") on the closing of a registered public offering ("Offering") of up to EUR7 billion, splitted into EUR500 million principal amount of floating rate senior notes due 2021, EUR1.5 billion principal amount of 0.000% senior notes due 2021, EUR1.5 billion principal amount of 0.375% senior notes due 2023, EUR1.5 billion principal amount of 1.125% senior notes due 2027, EUR1 billion principal amount of 1.625% senior notes due 2031 and EUR1 billion principal amount of 2.250% senior notes due 2039 (collectively, the "Notes").
Medtronic LuxCo's obligations under the Notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc., a wholly owned indirect subsidiary of Medtronic LuxCo ("Medtronic, Inc."), on a senior unsecured basis.
In addition, DLA Piper advised Covidien International Finance S.A. ("CIFSA") on its tender offering of several series of outstanding notes issued by Medtronic, Inc. and CIFSA ("Tender Offering").
Medtronic Global Holdings S.C.A, is a subsidiary of Medtronic plc, headquartered in Dublin, Ireland, being among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
The DLA Piper Luxembourg:
The team was led by Laurent Massinon (Partner, Finance, Projects & Restructuring) who was supported by Christina Nickel (Legal Advisor, Finance Projects & Restructuring), Jacques Wantz (Partner, Tax) and Emre Akan (Associate, Tax).